Table 3.

Thirty percent response rate to Brief Pain Inventory average pain

Study	Analysis	Treatment groupa	Responderb n (%)	P valuec
Study 1	BOCF	DLX 60/120 mg QD	50 (45.9)	0.056
		Placebo	38 (33.0)
	LOCF	DLX 60/120 mg QD	58 (53.2)	0.060
		Placebo	46 (40.0)
	mBOCF	DLX 60/120 mg QD	52 (47.7)	0.137
		Placebo	43 (37.4)
	aeBOCF	DLX 60/120 mg QD	53 (48.6)	0.226
		Placebo	46 (40.0)
Study 2	BOCF	DLX 60/120 mg QD	69 (57.0)	0.031
		Placebo	54 (42.5)
	LOCF	DLX 60/120 mg QD	79 (65.3)	<0.001
		Placebo	56 (44.1)
	mBOCF	DLX 60/120 mg QD	72 (59.5)	0.008
		Placebo	54 (42.5)
	aeBOCF	DLX 60/120 mg QD	72 (59.5)	0.008
		Placebo	54 (42.5)

^aStudy 1: N (DLX 60/120 mg QD) = 109, N (placebo) = 115.

Study 2: N (DLX 60/120 mg QD) = 121, N (placebo) = 127.

^bResponse was defined as at least a 30% reduction in BPI average pain.

^cP value comparison with placebo.

Abbreviations: aeBOCF, discontinuation due to adverse events only; BOCF, baseline observation carried forward; BPI, Brief Pain Inventory; DLX, duloxetine; LOCF, last observation carried forward; mBOCF, modified BOCF; MMRM, mixed-model repeated measures; N, number of patients in the specified category; QD, once daily.